Regulatory outlook in the AbbVie stock forecast 2025 points toward favorable FDA decisions on neurology drug candidates, enhancing sector leadership. These catalysts could help ABBV outperform broader pharma indices. Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance. We have seen $512,569 of award payments to $ABBV over the last year. The AbbVie stock forecast 2025 from sector specialists incorporates expectations of regulatory approvals for novel migraine and oncology treatments. This could help sustain revenue momentum above $65 billion annually, maintaining ABBV’s large-cap growth profile.